Haematology Chemotherapy

All protocols, consent forms and documents on this website are for the use of St Luke’s Cancer Alliance staff only.
For those who do not work within St Luke’s Cancer Alliance:
Use of this site and any information on it is at your own risk. We do not accept responsibility for reliance on any drug doses that may be set out on the website. You assume full responsibility for the use of the information.

British Committee for Standards in Haematology: www.bcshguidelines.com/

NCI CTC (Common Terminology Criteria for Adverse Events) Version 4

Haematology index

Chemotherapy algorithm for AML
Chemotherapy algorithm for CML
Chemotherapy algorithm for Myeloma
Chemotherapy algorithm for DLBCL
Chemotherapy algorithm for Indolent Lymphomas (excluding mantle cell and SLL)
Chemotherapy algorithm for Hodgkin’s Lymphoma
Chemotherapy algorithm for CLL

Acute Myeloid Leukaemia (AML)

AIDA (for APL)
Azacitidine
Cytarabine (subcut)
High dose cytarabine
DA
FLAG
FLAG-Ida
Lenalidomide for MDS
MIDAC
Tretinoin

AL Amyloidosis (protocols from the National Amyloidosis Centre)

CVD (low dose) for advanced Mayo Stage III
CVD (intermediate dose) for Mayo Stage II or earlier/fitter Stage III
CVD (21 day cycle) for Mayo Stage I and selected Stage II

Auto-immune diseases (non-malignant)

Rituximab for autoimmune disease

Hairy Cell Leukaemia

Cladribine
Interferon-alfa
Pentostatin

Hodgkin’s Lymphoma

ABVD
BEACOPP-14
ChLVPP
Nivolumab

Multiple Myeloma

Benda-Thal-Dex (BDT)
Bortezomib, Dexamethasone & Cyclophosphamide (CVD)
Bortezomib & Dexamethasone +/-  Thalidomide (1st line for patients suitable for autograft)
Nursing Assessment Tool for Bortezomib
Carfilzomib & Dexamethasone
CTD & CTDa
Cyclophosphamide Weekly
High Dose Dexamethasone
DT-PACE
LCD
MPT
PAD
Panobinostat & Bortezomib
Pomalidomide
Thalidomide

Lenalidomide Prescription Authorisation Form

Pomalidomide Prescription Authorisation Form
Pomalidomide Male Treatment Forms
Pomalidomide Women Of Child Bearing Potential Treatment initiation form
Pomalidomide Women Of Non Child Bearing Potential Treatment initiation form

Thalidomide male treatment initiation form
Thalidomide Women of childbearing potential treatment initiation form
Thalidomide Women non child bearing potential treatment initiation form
Thalidomide Prescription authorisation form

Myeloproliferative / dysplastic Disorders

Anagrelide
Bosutinib
Busulfan
Dasatinib
Oral Etoposide
Hydroxycarbamide
Imatinib
Interferon-alfa
Nilotinib
Ponatinib
Ruxolitinib
Vinblastine-based regimen for LCH

Non-Hodgkin’s Lymphoma & CLL

Alemtuzumab
Link to Clinigen, for Alemtuzumab patient access form: https://cliniport.co.uk/
Clinigen Form for clinician or pharmacist registration
Guidelines for CMV Management

High Dose Methylprednisolone
High dose Methotrexate & HD Cytarabine for CNS lymphoma
High dose Methotrexate for CNS prophylaxis
Ibrutinib
Intrathecal MTX & Cytarabine & Hydrocortisone
Obinutuzumab + Bendamustine
Obinutuzumab + Chlorambucil
Pixantrone
R-Bendamustine-90 for low grade NHL
R-Bendamustine for CLL
Chlorambucil +/- Rituximab for CLL
Chlorambucil +/- Rituximab for low grade lymphomas
R-CHOP
R-CVP
R-FC
R-GCVP
R-Idelalisib
Rituximab Intravenous (includes monotherapy & maintenance)
Rituximab SUBCUTANEOUS for maintenance therapy
R-High Dose Methylprednisolone
R-Maxi CHOP + HD Cytarabine (Nordic regimen)
Venetoclax
Venetoclax – aide for patient, for titration phase

Second line / salvage regimens for Lymphoma

Brentuximab Vedotin
ESHAP
GDP
GEM-P
IVE
mini-BEAM
Rituximab

Peripheral Blood Stem Cell Mobilisation

Use appropriate tertiary centre protocol, to be supplied by tertiary centre at time of treatment, and a copy placed in the patient’s notes.